Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : final analysis of the GioTag studyHochmair, Maximilian J (Avtor) Morabito, Alessandro (Avtor) Hao, Desiree (Avtor) Yang, Cheng-Ta (Avtor) Soo, Ross A (Avtor) Yang, James C-H (Avtor) Gucalp, Rasim (Avtor) Halmos, Balazs (Avtor) Märten, Angela (Avtor) Čufer, Tanja (Avtor) non-small cell lung carcinoma -- therapydrug therapyafatinibosimertinibGioTag studyAim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment >/=10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients.Future Medicine Ltd20202020-11-18 13:29:03Neznano12685UDK: 616-006ISSN pri članku: 1744-8301DOI: 10.2217/fon-2020-0740COBISS_ID: 37424899OceCobissID: 521824025sl© 2020 Maximilian J. Hochmair and other authors